GDC-0134
/ Roche
- LARVOL DELTA
Home
Next
Prev
1 to 14
Of
14
Go to page
1
August 27, 2025
Pinpointing novel targets for osteoarthritis: A comprehensive cross-omics integration analysis.
(PubMed, Medicine (Baltimore))
- "Molecular docking results showed that GDC-0134 could effectively target DLK1, which provided a new target for targeted therapy of DLK1...USP8 and DLK1 were highlighted as promising therapeutic targets. These results offer promising avenues for creating novel therapies aimed at modifying OA progression."
Journal • Immunology • Osteoarthritis • Pain • Rheumatology • USP8
January 12, 2022
A Phase 1 study of GDC-0134, a dual leucine zipper kinase inhibitor, in ALS.
(PubMed, Ann Clin Transl Neurol)
- "This trial characterized GDC-0134 safety and PK, but no adequately tolerated dose was identified. NFL elevations in GDC-0134-treated patients and DLK cKO mice raised questions about interpretation of biomarkers affected by both disease and on-target drug effects. The safety profile of GDC-0134 was considered unacceptable and led to discontinuation of further drug development for ALS. Further work is necessary to understand relationships between neuroprotective and potentially therapeutic effects of DLK knockout/inhibition and NFL changes in patients with ALS."
Journal • P1 data • Amyotrophic Lateral Sclerosis • CNS Disorders • Hematological Disorders • Optic Neuritis • Pain • Thrombocytopenia • MAPK8 • Plasma NfL
April 09, 2021
"my transcript of GDC-0134 #ACSSpring2021"
(@egonwillighagen)
April 09, 2021
"Question: does GDC-0134 reverse disease or merely slow progression? Answer: We see slowing of disease #ACSSpring2021"
(@cenmag)
April 09, 2021
"GDC-0134 #ACSSpring2021"
(@cenmag)
March 28, 2021
[VIRTUAL] Discovery of GDC-0134: A potent, selective, and brain-penetrant dual leucine zipper kinase Inhibitor
(ACS-Sp 2021)
- "In this presentation, we will highlight our approach to balancing the property space of kinase inhibitors for the CNS. Starting from a high-throughput screening hit, we used structure-based drug design combined with a focus on CNS drug-like properties to identify GDC-0134, which advanced to clinical evaluation as a potential treatment of amyotrophic lateral sclerosis (ALS)."
Amyotrophic Lateral Sclerosis • CNS Disorders • Complement-mediated Rare Disorders
October 15, 2020
"Discontinuations: RG7861 (anti S aureus ADC?) partnered with $SGEN. RG6000 = dual leucine zipper kinase inhibitor for ALS. $RHHBY"
(@JacobPlieth)
August 09, 2020
A Study of GDC-0134 to Determine Initial Safety, Tolerability, and Pharmacokinetic Parameters in Participants With Amyotrophic Lateral Sclerosis
(clinicaltrials.gov)
- P1; N=54; Completed; Sponsor: Genentech, Inc.; Active, not recruiting ➔ Completed; Trial completion date: Aug 2020 ➔ Mar 2020; Trial primary completion date: Aug 2020 ➔ Mar 2020
Clinical • Trial completion • Trial completion date • Trial primary completion date • Amyotrophic Lateral Sclerosis • CNS Disorders • Complement-mediated Rare Disorders • Pain
January 23, 2020
A Study of GDC-0134 to Determine Initial Safety, Tolerability, and Pharmacokinetic Parameters in Participants With Amyotrophic Lateral Sclerosis
(clinicaltrials.gov)
- P1; N=54; Active, not recruiting; Sponsor: Genentech, Inc.; Recruiting ➔ Active, not recruiting; N=82 ➔ 54
Clinical • Enrollment change • Enrollment closed
December 23, 2019
A Study of GDC-0134 to Determine Initial Safety, Tolerability, and Pharmacokinetic Parameters in Participants With Amyotrophic Lateral Sclerosis
(clinicaltrials.gov)
- P1; N=82; Recruiting; Sponsor: Genentech, Inc.; Active, not recruiting ➔ Recruiting; Trial completion date: Oct 2019 ➔ Aug 2020; Trial primary completion date: Oct 2019 ➔ Aug 2020
Clinical • Enrollment open • Trial completion date • Trial primary completion date
August 06, 2019
A Study to Determine the Bioavailability of Various Formulations of GDC-0134 in Healthy Female Participants of Non-Childbearing Potential
(clinicaltrials.gov)
- P1; N=49; Completed; Sponsor: Genentech, Inc.; Active, not recruiting ➔ Completed
Clinical • Trial completion
August 05, 2019
A Study of GDC-0134 to Determine Initial Safety, Tolerability, and Pharmacokinetic Parameters in Participants With Amyotrophic Lateral Sclerosis
(clinicaltrials.gov)
- P1; N=82; Active, not recruiting; Sponsor: Genentech, Inc.; Recruiting ➔ Active, not recruiting
Clinical • Enrollment closed
May 07, 2019
A Study to Determine the Bioavailability of Various Formulations of GDC-0134 in Healthy Female Participants of Non-Childbearing Potential
(clinicaltrials.gov)
- P1; N=44; Active, not recruiting; Sponsor: Genentech, Inc.; Recruiting ➔ Active, not recruiting
Clinical • Enrollment closed
February 15, 2019
A Study to Determine the Bioavailability of Various Formulations of GDC-0134 in Healthy Female Participants of Non-Childbearing Potential
(clinicaltrials.gov)
- P1; N=44; Recruiting; Sponsor: Genentech, Inc.; Not yet recruiting ➔ Recruiting
Clinical • Enrollment open
1 to 14
Of
14
Go to page
1